Upcoming Conferences
- Advanced Therapies Week 2027 18-21 January, 2027
- Advanced Therapies UK 2027 9-10 March 2027
Other events
Learning Center
Latest on our Blog
More on the blog
Investor Relations

REPROCELL Corporate News

Corporate News Archive

Oct 12, 2026

REPROCELL Launches REPROSKIN™ as Both a Research Product and Contract Testing Service

Sep 28, 2026

REPROCELL and Polyphron Announce Collaboration to Advance AI-Driven Human Tissue Research Using StemRNA™ iPSCs

Jul 27, 2026

REPROCELL Expands Clinical iPSC and Stem Cell Solutions in China Through Strategic Collaboration with WEIPU Biotechnology

Jun 24, 2026

REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)

Jun 02, 2026

REPROCELL Receives Commercialization Award from Maryland Stem Cell Research Fund to Advance Universal, Hypoimmune iPSC Platforms

Jun 01, 2026

REPROCELL Researchers Co-Author New Study Demonstrating the Potential of AI-Driven Drug Response Prediction for IBD Patients

Apr 09, 2026

REPROCELL USA Inaugurates GMP-Compliant Cell Culture Facility

Mar 03, 2026

REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

Mar 02, 2026

REPROCELL Expands Product Portfolio with Addition of BioThrust™ ComfyCell Incu Bioreactor Platform

Jan 28, 2026

REPROCELL Launches StemEdit: Clinical Gene Editing Services and New iPSC Lines Using AI-Designed Editing System

Nov 07, 2025

REPROCELL Announces the Commercial Launch of its StemEdit Hypoimmune hiPSC Lines Generated with Advanced Gene Editing Innovations

Oct 22, 2025

REPROCELL USA Receives Funding from the Maryland Stem Cell Research Fund (MSCRF)

Oct 21, 2025

REPROCELL Launches Next-Generation System for 3D Bioengineered Tissues

Oct 20, 2025

REPROCELL and Histocell Achieve GMP Certification for Manufacturing Process of Clinical-Grade iPSC Master and Working Cell Banks Using StemRNA™ Clinical iPSCs

Aug 21, 2025

REPROCELL Launches ReproRegistry to Strengthen Access to Human Skin Samples for Research

Aug 20, 2025

REPROCELL Unveils Cutting-Edge Neoantigen Detection Service to Propel Precision Cancer Immunotherapy

Aug 13, 2025

REPROCELL and Durham University Researchers Develop iPSC-Derived Full-Thickness Human Skin Model

Jul 22, 2025

REPROCELL Announces U.S. FDA Drug Master File Submittal for StemRNA™ Clinical iPSC Seed Clones

Jul 02, 2025

Scottish Health Minister Visits REPROCELL Japan to Strengthen Life Sciences Collaboration

May 05, 2025

REPROCELL Launches Immune Modulated iPSC Products

Apr 25, 2025

Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment "Stemchymal®"

Feb 06, 2025

Gameto Announces FDA IND Clearance for Fertilo utilizing REPROCELL’s StemRNA™ Clinical Seed iPSCs

Jan 14, 2025

World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body

Jan 10, 2025

PRESS RELEASE: Qkine announces partnership with REPROCELL: Global distributorship for high quality bioactive proteins for stem cell culture

Nov 13, 2024

PRESS RELEASE: New Study Highlights Role of Stromal Support in Bioengineered Human Intestinal Models

Jul 22, 2024

PRESS RELEASE: Bioserve India Launches Advanced Stem Cell Products

May 30, 2024

REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells

May 17, 2024

PRESS RELEASE: Bioserve Biotechnologies and RISVI Trading Announce New Distributorship Agreement in Qatar

May 16, 2024

PRESS RELEASE: Our StemRNA Clinical Seed iPSCs Power Breakthrough in Women's Health!

May 14, 2024

PRESS RELEASE: REPROCELL Announces Partnership with Nova Natura UAB, Expanding Distribution Reach in Baltic Region

Apr 18, 2024

New from REPROCELL: GMP Grade Stem Cell Master Cell Bank Service Expansion

Feb 08, 2024

PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)

Jan 31, 2024

Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu

Jan 15, 2024

Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives

Dec 15, 2023

End of 2023 Newsletter

Oct 24, 2023

REPROCELL supports Silo Pharma with successful human tissue testing in Rheumatoid Arthritis study

Oct 04, 2023

REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs

Sep 27, 2023

Bioserve Biotechnologies Partners with BioMavericks Ltd. to Expand Presence in the UK market

Jul 13, 2023

Innovation Unleashed: REPROCELL's Q1 Recap and Insights

Jul 11, 2023

Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services

Jun 28, 2023

Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer

Jun 01, 2023

Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform

May 25, 2023

[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia

May 23, 2023

REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products

May 04, 2023

End of Q4 update from REPROCELL (2022-23)

May 03, 2023

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

Feb 28, 2023

Celebrating the 20th Anniversary of REPROCELL: A letter from our CEO Chikafumi Yokoyama

Dec 12, 2022

End of Q3 update from REPROCELL (2022-23)

Dec 09, 2022

Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue

Nov 23, 2022

REPROCELL invests in Histocell, S.L. a Spain-based CDMO

Nov 09, 2022

Building economic resilience and unleashing productivity through digital innovation

Oct 13, 2022

REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers

Oct 05, 2022

REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs

Oct 04, 2022

REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs

Oct 03, 2022

End of Q2 update from REPROCELL (2022-23)

Aug 31, 2022

REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine

Aug 17, 2022

Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials

Aug 15, 2022

Life science after lockdown: SPS returns for 2022

Aug 09, 2022

Bioserve India granted NABL accreditation in the field of Genomics Testing

May 16, 2022

Completion of Clinical Phase II Trials of Stemchymal in Japan

Mar 08, 2022

REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development

Jan 21, 2022

REPROCELL spotlights the power of smarter biospecimens in new global publication

Oct 25, 2021

Hoth Therapeutics Extends Partnership Agreement with REPROCELL

Sep 15, 2021

Bioserve India to sponsor webinar hosted by the Society of Fetal Medicine

Sep 02, 2021

REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service

Aug 18, 2021

REPROCELL signs MSA with TEXCELL for Master Cell Bank Manufacturing

Jul 05, 2021

REPROCELL highlights the power of human fresh tissue in global publication

Jun 29, 2021

REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite

Jun 21, 2021

REPROCELL Launch New Testing Service for Identification of the Indian (Delta) Covid-19 variant

May 24, 2021

Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan

May 18, 2021

VIROCLINICS-DDL announces renewal of collaboration agreement with REPROCELL

Apr 21, 2021

REPROCELL will participate at the Biotechgate Digital Partnering Event.

Apr 19, 2021

19 April 2021 – Bioserve Biotechnologies India Pvt. Ltd. launches clinical oncology diagnostic services in India.

Apr 08, 2021

Launch of New Testing Service of Identification for Covid-19 Variants

Mar 22, 2021

REPROCELL collaborates with Blacktrace Holdings in the sales of Nadia series, single-cell analysis system, in Japan

Mar 17, 2021

REPROCELL Regenerative Medicine Center officially certified as a manufacturing facility for cell culture products

Mar 15, 2021

Hoth Therapeutics Executes Partnership Agreement with REPROCELL to Assess the Effect of HT-003 Therapeutic Platform on Inflammatory Bowel Disease

Mar 11, 2021

Bioserve Biotechnologies India Pvt. Ltd. launches NIPT clinical services in India

Mar 01, 2021

New publication on RNA reprogramming of endothelial progenitor cells to make clinically -relevant iPSCs

Mar 01, 2021

REPROCELL launches PCR Testing Service for COVID-19

Feb 25, 2021

REPROCELL completes patient registration for phase II clinical trial of regenerative therapeutic Stemchymal®

Feb 16, 2021

Axion BioSystems makes REPROCELL a distributor of its Maestro systems and consumables

Dec 17, 2020

REPROCELL launches personalized iPSC production service alongside new B2C website for "Personal iPS" customers

Dec 10, 2020

REPROCELL Becomes VIP Supplier on Scientist.com Biotech Marketplace

Aug 17, 2020

REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research

Jul 16, 2020

eTheRNA-led international consortium starts preclinical studies of cross-strain protective COVID-19 mRNA vaccine for high risk populations

Jul 15, 2020

REPROCELL announce the launch of StemRNA™ Entero human iPSC-derived intestinal epithelial cells

Jul 15, 2020

REPROCELL’s Personal iPS Service is Launched in Japan

Jul 13, 2020

Why eTheRNA's mRNA vaccine may offer a long-term solution to COVID

Feb 28, 2020

Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient

Feb 13, 2020

Prof Stefan Przyborski to give Keynote Address at this year’s SMi 3D Cell Culture Conference

Jan 16, 2020

Patients with IBD absorb drugs differently from healthy individuals

Jan 14, 2020

REPROCELL can now predict oral bioavailability in fresh IBD tissue

Dec 23, 2019

Early understanding of pharmacology and genomics can improve precision medicine strategies

Nov 13, 2019

Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services

Nov 04, 2019

Appointment of New Distributor in Thailand

Oct 25, 2019

REPROCELL Receives MSCRF Grant to Accelerate Stem Cell Drug Discovery Capability for Enabling Neuronal Disease Research and Drug Development

Sep 25, 2019

PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe

Aug 28, 2019

PRESS RELEASE: Axion BioSystems make REPROCELL a product distributor

Aug 22, 2019

PRESS RELEASE: ABLE Biott Bioreactors now available in Europe

May 13, 2019

REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders

Apr 24, 2019

REPROCELL and Hanugen to custom manufacture clinical grade oligos for gene therapy

Apr 08, 2019

REPROCELL USA Inc. Achieves Quality Management ISO9001:2015 Certification

Mar 14, 2019

UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine

Mar 12, 2019

REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development

Feb 28, 2019

REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories

Feb 01, 2019

Appointment of New Distributor in China

Oct 10, 2018

ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production

Oct 09, 2018

REPROCELL announces the launch of a cutting-edge iPS cell genome editing service utilizing next-generation CRISPR/Cas9 technology: SNIPER

Aug 01, 2018

Steminent Announces Japan partner REPROCELL has PMDA Approval of CTN for Phase II Trial of Stemchymal® SCA in the Treatment of Spinocerebellar Ataxia in Japan

Jun 21, 2018

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

Jun 13, 2018

REPROCELL’s footprint extends to serve life sciences in India

Apr 26, 2018

Acquisition of BioServe Biotechnologies India Pvt. Ltd.

Apr 18, 2018

REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon

Apr 06, 2018

Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow

Mar 21, 2018

REPROCELL’s David Bunton addresses the Scottish Parliament

Mar 14, 2018

Patient-derived tumor organoids recapitulate clinical treatments

Jan 24, 2018

REPROCELL’s Prof Stefan Przyborski to chair the SMi 2nd Annual Conference on 3D Cell Culture – London UK, 21-22 February 2018

Jan 19, 2018

Formation of human tissue to improve drug testing and reduce animal research

Jan 15, 2018

REPROCELL Launches New Global Website

Nov 29, 2017

REPROCELL Announces Research Collaboration with Q Therapeutics and Dr Mahendra Rao

Nov 08, 2017

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

Sep 27, 2017

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

Aug 10, 2017

Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)

Aug 10, 2017

Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow

May 24, 2017

REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India

Apr 13, 2017

REPROCELL and Fox Chase Cancer Center Form Strategic Alliance to Accelerate Biomarker and Genetic Discovery

Mar 03, 2017

REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research

Feb 14, 2017

REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan

Feb 07, 2017

Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination

Jan 13, 2017

Prof Stefan Przyborski to chair the SMi Group’s 3D Cell Culture 2017 Conference (22-23 Feb)

Nov 22, 2016

Notice of formation of contract with Healios K.K. for testing services for regenerative pharmaceutical products

Nov 16, 2016

Notice of formation of contract with FANCL Corp. for human iPS cell-derived model cell development

Nov 11, 2016

Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy

Sep 16, 2016

REPROCELL Europe wins CV Technology Innovator Awards 2016 for Alvetex

Jul 06, 2016

Prof Stefan Przyborski speaking at BBS 2016 Biennial Meeting

May 20, 2016

REPROCELL Europe’s (formerly Reinnervate’s) CSO Prof Stefan Przyborski to give an Alvetex Seminar at the University of Oxford, 24 May 2016

May 13, 2016

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

Apr 21, 2016

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

Mar 22, 2016

Reinnervate Ltd wins Corporate Vision’s 2015 Technology Innovator Award for Alvetex

Jan 14, 2016

Alvetex in Space

Nov 25, 2015

REPROCELL acquires Biopta to expand its drug discovery services

Nov 18, 2015

Biopta co-authors research in the European Respiratory Journal

Nov 18, 2015

Publication of Paper on “3D culture model construction of mouse neurons” in Neuroscience Letters

Nov 16, 2015

A Joint Development with the National Cancer Center Information Regarding the Sale of “ReproHP Medium,” a Culture Fluid for Human Primary Liver Cells with High Levels of Functionality

Nov 04, 2015

Notice of Passage of Examination for United States Patent Application Concerning Amplification Method of Hematopoietic Stem Cells

Oct 19, 2015

REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others

Oct 14, 2015

The REPROCELL Group announces publication of a paper on its state-of-the-art RNA Reprogramming technology in Human Gene Therapy, an international journal

Sep 08, 2015

REPROCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells

Aug 26, 2015

Announcement: New High Performance Cryopreservation Solution – ReproCryo DMSO Free

Aug 14, 2015

Announcement of Award for Prototype Development of Large-Scale Production on Human-iPSC derived Cardiomyocytes

Jul 29, 2015

Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”

Jul 21, 2015

Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells

Jul 01, 2015

Announcement of Award for Prototype Development of a Liver Cell Kit

Jun 30, 2015

Stemgent, a REPROCELL Group Company Announces a New High Performance Self-replicative RNA Reprogramming Kit

Jun 04, 2015

REPROCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells

Apr 20, 2015

Alvetex® 3D cell culture platform reaches new heights with project aboard the International Space Station (ISS).

Mar 05, 2015

New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system

Feb 02, 2015

RSC book publication: Human-based systems for translational research

Jan 13, 2015

Biopta and Proteon publish new research in Journal of Cardiovascular Pharmacology

Oct 08, 2014

Alvetex Scaffold 384 well plates used in an Oncology HTS program by AstraZeneca

Sep 09, 2014

REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA)

Aug 05, 2014

Stem Cell Company REPROCELL (Japan) Acquires 3D Cell Culture Company Reinnervate (UK) and Human Tissue Supplier BioServe (USA)

Feb 25, 2014

Scottish company creates first searchable database of human pharmacological responses in functional intact tissues

Feb 05, 2014

Launch of Reinnervate Perfusion System for 3D cell culture

Nov 13, 2013

Biopta collaborates with Merck to investigate in vivo cardiac effects

Nov 04, 2013

Reinnervate Ltd partners with Oncotest and SBH Sciences on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture

Sep 19, 2013

Reinnervate Ltd and Roslin Cellab to partner around 3D stem cell printing products and technologies

Aug 22, 2013

Prof. Stefan Przyborski to participate at the XCellR8 Human Primary Cell Culture course, 7 November 2013

Jul 31, 2013

Alvetex 3D cell culture scaffolds chosen by investigators at Massachusetts General Hospital for study of bone loss during space flight

Apr 23, 2013

Scottish SMEs Announce Collaboration with Universities, Industry and NHS in Establishment of a £20m Stratified Medicine Scotland Innovation Centre

Jan 07, 2013

3D cell culture firm Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement

Dec 14, 2012

3D cell culture firm Reinnervate announces the release of Alvetex®Scaffold 96 well plates for high throughput 3D cell-based assays

Jul 09, 2012

Medicyte GmbH and Reinnervate Ltd to collaborate on development of next generation predictive 3D cell toxicity assays

Jun 27, 2012

Top award for 3D cell culture pioneer, Stefan Przyborski, of Reinnervate Ltd

Jun 17, 2012

Reinnervate and Tecan to develop automated 3D cell culture solutions for improved cellular assays

Apr 30, 2012

Reinnervate Ltd and Roslin Cellab announce plans to collaborate

Mar 30, 2012

Reinnervate Ltd announce Kirkstall Ltd collaboration

Nov 16, 2011

Reinnervate and Mirus Bio announce collaboration with the launch of the new 3D Transfection System for the transfection of cells cultured in Alvetex®

Jun 27, 2011

Alvetex® voted one of most technologically significant new research products by R&D magazine

Dec 06, 2010

Alvetex® named in the top ten life science innovations of 2010 by The Scientist magazine

Nov 22, 2010

Reinnervate launches Alvetex®, a breakthrough product for enabling routine 3D cell culture

Nov 17, 2010

Reinnervate completes expansion into new purpose-built facility at NETPark

Sep 28, 2010

Reinnervate’s ec23® shown to enhance neuronal differentiation of human fetal neuroprogenitors and human embryonic stem cells

Sep 28, 2010

Reinnervate wins Chemistry Innovation / EPSRC Industrial CASE Award to fund development of Alvetex® for the 3D culture of liver cells

Sep 14, 2010

Reinnervate has been accepted as a new member of the In Vitro Testing Industrial Platform (IVTIP)

May 27, 2010

Reinnervate secures £1.8 million of investment to support commercialisation of Alvetex